Bendamustine: an old drug in the new era for patients with non-hodgkin lymphomas and chronic lymphocytic leukemia.
In conclusion, bendamustine as a single agent or in combinations has shown activity with acceptable toxic profile in the treatment of patients with indolent NHLs or CLL without del(17p) mutation.
PMID: 31168188 [PubMed - in process]
Source: Acta Clinica Croatica - Category: General Medicine Tags: Acta Clin Croat Source Type: research
More News: Chemotherapy | Chronic Leukemia | Chronic Lymphocytic Leukemia | Croatia Health | General Medicine | Leukemia | Lymphoma | Non-Hodgkin's Lymphoma | Rituxan | Study | Toxicology | Treanda